ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет Архив журнала 2004 год № 1-2

Щитовидная железа и липиды: современные представления

Леонидас Дунтас (Leonidas H. Duntas)
Профессор по внутренним болезням и эндокринологии медицинской школы университета Ульма (Германия)



ЛИТЕРАТУРА

  1. Vanderpump M.P., Tunbridge W.M. Epidemiology and prevention of clinical and subclinical hypothyroidism. // Thyroid — 2002 — Vol. 12. — P. 839 — 847.
  2. Muls E., Rosseneu M., Blanton V., et al. Serum lipids and apolipoproteins A- I, A-II, and B in primary hypothyroidism before and during treatment. // Eur J Clin Invest — 1984 — Vol. 14. — P. 12 — 15.
  3. Obrien T., Katz K., Hodge D., et al. The effect of treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII, and E. // Clin Endocrinol — 1997 — Vol. 46. — P. 17 — 20.
  4. Duntas LH. Thyroid disease and lipids. // Thyroid — 2002 — Vol. 12. — P. 287-293.
  5. Bindels A.J., Westendorp R.G., Frolich M., et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case finding. // Clin Endocrinol — 1999 — Vol. 50. — P. 217-220.
  6. Kanaya A.M., Harris F., Volpato S., et al. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. // Arch Intern Med - 2002 — Vol. 162. — P. 773 — 779.
  7. Althaus B.U., Staub J.J., Ryff-de Leche A., et al. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary artery disease. // Clin Endocrinol — 1988 — Vol. 28. — P. 157 — 163.
  8. Tieche M., Lupi G.A., Gutzwiller F., et al. Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease? // Br Heart J — 1981 — Vol. 46. — P. 202 — 206.
  9. Cooper D.S., Halpern R., Wood L.C., et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo controlled trial. // Ann Intern Med — 1984 — Vol. 101. — P. 18 — 24.
  10. Ridgway E.C., Cooper D.S., Walker H., et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. // J Clin Endocrinol Metab — 1981 — Vol. 53. — P. 1238.
  11. Efstathiadou Z., Bitsis S., Milionis H.J., et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? // Eur J Endocrinol — 2001 — Vol. 145. — P. 705 — 710.
  12. Danese M.D., Ladenson P.W., Meinert C.L., Powe N.R. Eeffect of thyroxin therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 2993 — 3001.
  13. Caraccio N., Ferrannini E., Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomised placebo-controlled study. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 1533 — 1538.
  14. Valemarsson S., Nilson-Ehle P. Hepatic lipase and the clearing reaction: studies in euthyroid and hypothyroid subjects. // Horm Metab Res — 1987 — Vol. 19. — P. 28 — 30.
  15. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies. // Biochem Biophys Acta — 1994 — Vol. 1215. — P. 209 — 236.
  16. Walton K.W., Scott P.J., Dykes P.W., Davies J. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131I-low-density lipoproteins in hypothyroidism and thyrotoxicosis. // Clin Sci — 1965 — Vol. 29. — P. 217 — 224.
  17. Shin D.J., Osborne T.F. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein (SREBP-2). // J Biol Chem — 2003 — Vol. 278. — P. 34114 — 34118.
  18. Dredecjus M., Masson D., Gautier T., et al. Low cholesteryl ester transfer protein (CETP) concentration, normal CETP activity in serum from patients with shortterm hypothyroidism. Lack of relationship to lipoprotein abnormalities. // Clin Endocrinol — 2003 — Vol. 58. — P. 581 — 588.
  19. Franco M., Castro G., Romero L., et al. Decreased activity of lecithin: acyltransferase and hepatic lipase in chronic hypothyroid rats: implications for reverse cholesterol transport. // Mol Cell Biochem — 2003 — Vol. 246 — P. 51-56.
  20. Liu X.Q., Rahman A., Bagdade J.D., et al. Effect of thyroid hormone on plasma apolipoproteins and apo-A and apo B-containing lipoprotein particles. // Eur J Clin Invest — 1998 — Vol. 28. — P. 266 — 270.
  21. Nikolaeva A.V., Pimenov L.T. Lipid metabolism and functional status of the kidney in hypothyroid patients depending on the phase of disease. // Ter Arkh — 2002 — Vol. 74. — P. 20 — 23.
  22. Pucci E., Chiovato L., Pinchera A. Thyroid and lipid metabolism. // Int J Obes Relat Metab Disord — 2000 - Suppl 2. — P. 109 — 112.
  23. Tan K.C., Shiu S.W., Kung A.W. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 140 — 143.
  24. Zambon A., Bertocco S., Vitturi N., et al. Relevance of hepatic lipase to the metabolism of triacylglycerol rich lipoproteins. // Biochem Soc Trans — 2003 — Vol. 31. — P. 1070 — 1074.
  25. Sacks F.M., Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 4525 - 4532.
  26. Campos H., Blijlevens E., McNamara J.R., et al. Low density lipoprotein particle size distribution: results from the Framingham offspring Study. // Arterioscler Thromb — 1992 — Vol. 12. — P. 1410 — 1419.
  27. White A.L., Lanford R.E. Biosynthesis and metabolism of lipoprotein(a). // Curr Opin Lipidol — 1995 — Vol. 6. — P. 75 — 80.
  28. Schaefer E.J., Lamon-Fava S., Jenner J.L., et al. Lipoprotein (a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. // JAMA — 1994 — Vol. 271 — P. 999 — 1003.
  29. Bostom A.G., Gagnon D.R., Cupples L.A., et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. // Circulation — 1994 — Vol. 90. — P. 1688 — 1695.
  30. Klausen I.C., Nielsen F.E., Hegedus L., et al. Treatment of hypothyroidism reduces lowdensity lipoproteins but not lipoprotein (a). // Metabolism — 1992 — Vol. 41. — P. 911 — 914.
  31. Pazos F., Alvarez J.J., Rubies-Prat J., et al. Long term thyroid replacement therapy and levels of lipoprotein (a) and other lipoproteins. // J Clin Endocrinol Metab — 1995 — Vol. 80. — P. 562 — 566.
  32. Alvarez J.J., Lasuncion M.A., Olmos J.M., Herrera E. Interindividual variation in the partition of lipoprotein(a) into lipoprotein subfractions. // Clin Biochem — 1993 — Vol. 26. — P. 399 — 408.
  33. Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study. // Arch Intern Med — 2000 — Vol. 160. — P. 526 - 534.
  34. Staub J.J., Althaus B.U., Engler H., et al. Spectrum of subclinical and ouvert hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. // Am J Med — 1992 — Vol. 92. — P. 631 — 642.
  35. Vierhapper H., Nardi A., Grosser P., et al. Lowdensity lipoprotein cholesterol in subclinical hypothyroidism. // Thyroid — 2000 — Vol. 10. — P. 981 - 984.
  36. Luboshitzky R., Aviv A., Herer P., Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. // Thyroid — 2002 — Vol. 12. — P. 421 — 425.
  37. Milionis H.J., Efstathiadou Z., Tselepis A.D., et al. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. // Thyroid — 2003 — Vol. 13. — P. 365 - 369.
  38. Duntas L.H. Lipoprotein(a) and apolipoprotein(a) isoform size in thyroid disease: the quest for the golden fleece. // Thyroid — 2003 — Vol. 13. — P. 345 — 346.
  39. Ness G.C., Dugan R.E., Lakshmanan M.R., et al. Stimulation of hepatic b-hydroxy-methyl-glutaryl Coenzyme A reductase activity in hypophysectomized rats by L-triiodothyronine. // Proc Natl Acad Sci USA — 1973 — Vol. 70 — P. 3839 — 3842.
  40. Cachefo A., Boucher P., Vidon C., et al. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. // J Clin Endocrinol Metab — 2001 — Vol. 86 — P. 5353 — 5357.
  41. Riis A.L., Gravholt C.H., Djurhuus C.B., et al. Elevated regional lipolysis in hyperthyroidism. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 4747 — 4753.
  42. Bell G.M., Sawers J., Forfar J.C., et al. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. // Clin Endocrinol (Oxf). — 1983 — Vol. 18. — P. 511 — 551.
  43. Sawin C.T. Subclinical hyperthyroidism and atrial fibrillation. // Thyroid — 2002 — Vol. 12. — P. 501 — 503.
  44. Parle J.V., Maisonneuve P., Sheppard M.C., et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. // Lancet — 2001 — Vol. 358 — P. 861 — 865.
  45. Auer J., Scheibner P., Mische T., et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. // Am Heart J — 2001 — Vol. 142. — P. 838-842.
  46. Barth J.D., Jansen H., Kromhout D., et al. Diet and the role of lipoproteins lipases, and thyroid hormones in coronary lesion growth. // J Cardiovasc Pharmacol — 1987 (Suppl 9). — P. 42 — 46.
  47. Holvoet O., Stassen J.N., Van Cleemput J., et al. Correlation between oxidized low-density lipoproteins and coronary artery disease in heart transplant patients. // Arterioscler Thromb Vasc — 1998 — Vol. 18. — P. 100 — 107.
  48. Duntas L.H., Mantzou E., Koutras D.A. Circulating levels of oxidized low- density lipoprotein in overt and mild hypothyroidism. // Thyroid — 2002 — Vol. 12. — P. 1003 — 1007.
  49. Dieckman T., Demacker P.N., Kastelein J.J., et al. Increased oxidizability of low-density lipoproteins in hypothyroidism. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 1752 — 1755.
  50. Constantini F., Pierdomenico S.D., De Cesare D., et al. Effect of thyroid function on LDL oxidation. // Arterioscler Thromb Vasc Biol — 1998 — Vol. 18 — P. 732 — 737.
  51. Resch U., Helsel G., Tatzber F., Sinzinger H. Antioxidant status in thyroid dysfunction. // Clin Chem Lab Med — 2002 — Vol. 40. — P. 1132 — 1134.
  52. Raiszadeh F., Solati M., Etemadi A., Azizi F. Serum paraoxonase activity before and after treatment of thyrotoxicosis. // Clin Endocrinol — 2004 — Vol. 60. — P. 75 — 80.
  53. Sundaram V., Hanna H.F., Koneru L., et al. Both hypotyhyroidism and hyperthyroidism enhance low-density lipoprotein oxidation. // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 3241 — 3244.
  54. Benvenga S., Robbins J. Altered thyroid hormone binding to plasma lipoproteins in hypothyroidism. // Thyroid — 1996 — P. 3377 — 3378.
  55. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. — Nature — Vol. 362. — P. 801 — 809.
  56. Masuda J., Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. // Arteriosclerosis — 1990 — Vol. 10. — P. 178 — 187.
  57. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. // Proc Natl Acad Sci U.S.A. — 1991 — Vol. 88. — P. 5252 — 5256.
  58. Ross R., Masuda J., Raines E.W. Cellular interaction, growth factors and smooth muscle proliferation in atherogenesis. // Ann N.Y. Acad Sci — 1990 — Vol. 598. — P. 102 — 112.
  59. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modification of low-density lipoprotein that increase its atherogenicity. // N Engl J Med — 1989 — Vol. 320 — P. 915 — 924.
  60. Goldstein J.L., Brown M.S., Krieger M., et al. Demonstration of low density lipoprotein receptors in mouse teratocarcinoma stem cells and description of a method for producing receptor-deficient mutant mice. // Proc Natl Acad Sci USA — 1979 — Vol. 76. — P. 2843 — 2847.
  61. Mizuma H., Murakami M., Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. // Circ Res — 2001 — Vol. 88. — P. 313 — 318.
  62. Klein I., Ojamaa K. Thyroid hormone. Targeting the vascular smooth muscle cell. // Circ Res — 2001 — Vol. 88. — P. 260 — 263.
  63. Steinberg A.D. Myxedema and coronary artery disease - a comparative autopsy study. // Ann Intern Med — 1968 — Vol. 68. — P. 338 — 344.
  64. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. // Thyroid — 2000 — Vol. 10. — P. 665 — 679.
  65. Hak A.E., Pols H., Visser T.J., et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. // Ann Intern Med — 2000 — Vol. 132. — P. 270 — 278.
  66. Mya M.M., Aronow W.S. Subclinical hypothyroidism is associated with coronary arterial disease in older persons. // J Gerontol A Biol Sci Med Sci — 2002 — Vol. 57. — P. 658 — 659.
  67. Keating F., Parkin T.W., Selby J.B., Dickinson L.S. Treatment of heart disease associated with myxedema. // Prog Cardiovasc Dis — 1960 — Vol. 3. — P. 364 — 381.
  68. Pirich C., Mullner M., Sinzinger H. Prevalence and relevance of thyroid dysfunction in 1.922 cholesterol screening participants. // J Clin Epidemiol — 2000 — Vol. 53. — P. 623 — 629.
  69. Vanderpump M.P., Tunbridge W.M., French J.M., et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of a English community. // Thyroid — 1996 — Vol. 6. — P. 155 — 160.
  70. Bakker S.J., ter Maaten J.C., Popp-Snijders C., et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in euthyroid subjects. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 1206 — 1211.
  71. Anderson K.V., Odell P.M., Wilson P., Kannel W.B. Cardiovascular disease risk profiles. // Am Heart J — 1991 — Vol. 121. — P. 293 — 298.
  72. Kuusi T., Taskinen M.R., Nikkila E.A. Lipoproteins, lipolytic enzymes, and hormonal status in hypothyroid women at different levels of substitution. // J Clin Endocrinol Metab — 1988 — Vol. 66. — P. 51 — 56.
  73. Ito M., Takamatsu J., Matsuo T., et al. Serum concentration of remnant-like particles in hypothyroid patients before and after thyroxine replacement. // Clin Endocrinol (Oxf.) — 2003 — Vol. 58. — P. 621 — 626.
  74. Meier C., Straub J.J., Roth C.B., et al. TSH-controlled L-thyroxine therapy reduces cholesterol level and clinical symptoms in subclinical hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid Study). // J Clin Endocrinol Metab - 2001 — Vol. 86. — P. 4860 — 4866.
  75. Grover G.J., Mellstrom K., Ye L., et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. // Proc Natl Acad Sci USA — 2003 — Vol. 100. — P. 10067 — 10072.